Comparison of Proteomic Assessment Methods in Multiple Cohort Studies
- Raffield, L.M.
- Dang, H.
- Pratte, K.A.
- Jacobson, S.
- Gillenwater, L.A.
- Ampleford, E.
- Barjaktarevic, I.
- Basta, P.
- Clish, C.B.
- Comellas, A.P.
- Cornell, E.
- Curtis, J.L.
- Doerschuk, C.
- Durda, P.
- Emson, C.
- Freeman, C.M.
- Guo, X.
- Hastie, A.T.
- Hawkins, G.A.
- Herrera, J.
- Johnson, W.C.
- Labaki, W.W.
- Liu, Y.
- Masters, B.
- Miller, M.
- Ortega, V.E.
- Papanicolaou, G.
- Peters, S.
- Taylor, K.D.
- Rich, S.S.
- Rotter, J.I.
- Auer, P.
- Reiner, A.P.
- Tracy, R.P.
- Ngo, D.
- Gerszten, R.E.
- O&apos
- Bowler, R.P.
- NHLBI Trans-Omics for Precision Medicine (TOPMed) Consortium
DOIAbstract
Novel proteomics platforms, such as the aptamer-based SOMAscan platform, can quantify large numbers of proteins efficiently and cost-effectively and are rapidly growing in popularity. However, comparisons to conventional immunoassays remain underexplored, leaving investigators unsure when cross-assay comparisons are appropriate. The correlation of results from immunoassays with relative protein quantification is explored by SOMAscan. For 63 proteins assessed in two chronic obstructive pulmonary disease (COPD) cohorts, subpopulations and intermediate outcome measures in COPD Study (SPIROMICS), and COPDGene, using myriad rules based medicine multiplex immunoassays and SOMAscan, Spearman correlation coefficients range from −0.13 to 0.97, with ...